Gilteritinib is a selective FLT3 tyrosine kinase inhibitor primarily indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. To ensure the safety and efficacy… Read more




















Gilteritinib is a selective FLT3 tyrosine kinase inhibitor primarily indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. To ensure the safety and efficacy of this therapeutic agent, pharmaceutical laboratories rely on high-quality reference standards for rigorous analytical testing and quality control. This category contains a comprehensive range of Gilteritinib related compounds, including synthetic process-related impurities, degradation products, and metabolites, which are essential for precise impurity profiling and regulatory compliance. Furthermore, we provide stable isotope labelled compounds, such as deuterium-labelled variants, which serve as critical internal standards for accurate quantification in mass spectrometry-based assays. These materials are vital for method validation, forced degradation studies, and supporting the development of robust analytical protocols throughout the drug lifecycle.